Patents by Inventor Mari Posner
Mari Posner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9765065Abstract: Disclosed herein are compounds having formula (I) wherein a dashed line represents the presence or adsence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ester thereof; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis —CH2CH?CH—(CH2)3—, or —CH2C?C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o—, wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 —CH2— may be replaced by S or O, and 1 —CH2—CH2— may be replaced by —CH?CH— or —C?C—; U1 and U2 are independently selected from —H, ?O, —OH, —F, —Cl, and —CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.Type: GrantFiled: February 6, 2017Date of Patent: September 19, 2017Assignee: ALLERGAN, INC.Inventors: David W. Old, Vinh X. Ngo, Mark Holoboski, Mari Posner
-
Publication number: 20170144999Abstract: Disclosed herein are compounds having formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ester thereof; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis-CH2CH?CH—(CH2)3—, or —CH2C?C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o—, wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 —CH2— may be replaced by S or O, and 1 —CH2—CH2— may be replaced by —CH?CH— or —C?C—; U1 and U2 are independently selected from —H, ?O, —OH, —F, —Cl, and —CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.Type: ApplicationFiled: February 6, 2017Publication date: May 25, 2017Inventors: David W. Old, Vinh X. Ngo, Mark Holoboski, Mari Posner
-
Patent number: 9591935Abstract: Disclosed herein are compounds having the formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ether thereof; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis —CH2CH?CH—(CH2)3—, or —CH2C?C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o— wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 —CH2— may be replaced by S or O, and 1 —CH2—CH2— may be replaced by —CH?CH— or —C?C—; U1 and U2 are independently selected from —H, ?O, —OH, —F, —Cl, and —CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.Type: GrantFiled: June 30, 2008Date of Patent: March 14, 2017Assignee: ALLERGEN, INC.Inventors: David W. Old, Vinh X. Ngo, Mark Holoboski, Mari Posner
-
Patent number: 8487091Abstract: Disclosed herein are compounds represented by the formula: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: February 25, 2009Date of Patent: July 16, 2013Assignee: Allergan, Inc.Inventors: Mark Holoboski, Robert M. Burk, Mari Posner, Yariv Donde, David W. Old
-
Patent number: 8193373Abstract: Compound having the formula below are disclosed herein: formula (I). Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: December 4, 2007Date of Patent: June 5, 2012Assignee: Allergan, Inc.Inventors: Mark Holoboski, Robert M. Burk, Mari Posner
-
Patent number: 7964634Abstract: Compounds having a structure are disclosed herein. Compositions, methods, and medicaments related to the therapeutic use of these compounds are also disclosed.Type: GrantFiled: April 21, 2009Date of Patent: June 21, 2011Assignee: Allergan, Inc.Inventors: Yariv Donde, Jeremiah H. Nguyen, Mark Holoboski, Mari Posner, Robert M. Burk
-
Patent number: 7960378Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, R1, R2, Z, and G are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: March 17, 2009Date of Patent: June 14, 2011Assignee: Allergan, Inc.Inventors: Mark Holoboski, Robert M. Burk, Mari Posner
-
Publication number: 20090275646Abstract: Compounds having a structure are disclosed herein. Compositions, methods, and medicaments related to the therapeutic use of these compounds are also disclosed.Type: ApplicationFiled: April 21, 2009Publication date: November 5, 2009Applicant: ALLERGAN, INC.Inventors: Yariv Donde, Jeremiah H. Nguyen, Mark Holoboski, Mari Posner, Robert M. Burk
-
Publication number: 20090239930Abstract: Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, R1, R2, Z, and G are as described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: March 17, 2009Publication date: September 24, 2009Applicant: ALLERGAN, INC.Inventors: Mark HOLOBOSKI, Robert M. BURK, Mari POSNER
-
Publication number: 20090227573Abstract: Disclosed herein are compounds represented by the formula: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: February 25, 2009Publication date: September 10, 2009Applicant: ALLERGAN, INC.Inventors: Mark Holoboski, Robert M. Burk, Mari Posner, Yariv Donde, David W. Old
-
Publication number: 20070219262Abstract: The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula I: wherein the hatched segment represents an ? bonds, the solid triangle represents a ? bond, the wavy segments represent ? or ? bond, dashed lines represent a double bond or a single bond, X is selected from the group consisting of hydrogen and halogen radicals, R3 is heteroaryl or a substituted heteroaryl radical, R1 and R2 are independently selected from the group consisting of hydrogen or a lower alkyl radical having up to six carbon atoms, or a lower acyl radical having up to six carbon atoms, R is selected from the group consisting of CO2R4, CONR42, CH2OR4, CONR4SO2R4, P(O)(OR4) and wherein R4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4.Type: ApplicationFiled: June 6, 2007Publication date: September 20, 2007Inventors: Robert Burk, Mark Holoboski, Mari Posner
-
Publication number: 20060111430Abstract: Disclosed herein are compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, B, J, and E are further described. Methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: November 23, 2004Publication date: May 25, 2006Applicant: ALLERGAN, INC.Inventors: Yariv Donde, Mark Holoboski, Mari Posner, Robert Burk, Michael Garst
-
Publication number: 20050222094Abstract: A method is disclosed herein comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound represented by the general formula I; wherein A, B, D, X, Y, Z, R1, R3 and R4 are as defined in the specification.Type: ApplicationFiled: May 18, 2005Publication date: October 6, 2005Inventors: Robert Burk, Mark Holoboski, Mari Posner, Karen Kedzie, Daniel Gil
-
Publication number: 20050113338Abstract: The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula I: wherein the hatched segment represents an ? bonds, the solid triangle represents a ? bond, the wavy segments represent ? or ? bond, dashed lines represent a double bond or a single bond, X is selected from the group consisting of hydrogen and halogen radicals, R3 is heteroaryl or a substituted heteroaryl radical, R1 and R2 are independently selected from the group consisting of hydrogen or a lower alkyl radical having up to six carbon atoms, or a lower acyl radical having up to six carbon atoms, R is selected from the group consisting of CO2R4, CONR42, CH2OR4, CONR4SO2R4, P(O)(OR4) and wherein R4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4.Type: ApplicationFiled: October 26, 2004Publication date: May 26, 2005Inventors: Robert Burk, Mark Holoboski, Mari Posner